| Literature DB >> 29734740 |
Göran Högberg1, Tore Hällström2.
Abstract
Suicide attempts and suicidal ideation in adolescence are considered to be related to suicide and psychiatric adversity later in life. Secondary prevention by improving the treatment of suicidal youth is a distinct possibility. In this study, treatment with a systematised mood-regulation focused cognitive behavioural therapy (MR-CBT) (n = 15) was compared with treatment as usual (TAU) (n = 12) in a group of depressed adolescents in a clinical setting. MR-CBT focuses on mood regulation by means of counter conditioning with memory reconsolidation being the proposed mechanism of change. Subjects practice keeping emotionally positive memories to diminish the emotional impact of negative memories. Symptoms of depression were tested with a short version of the Mood and Feelings Questionnaire (SMFQ), and wellbeing with the World Health Organization 5 Wellbeing Index (WHO-5). Suicidal events were rated according to the clinical interview Columbia Suicide Severity Rating Scale (C-SSRS). Suicidal events at the end of treatment were significantly reduced in the MR-CBT group, but not in the TAU group. Depression and wellbeing improved significantly in both treatment groups. While far from conclusive, the results are encouraging enough to suggest that further studies should be undertaken to examine whether psychotherapy focusing on mood regulation for young individuals at risk might enhance secondary prevention of suicide.Entities:
Keywords: adolescents; counter-conditioning; memory reconsolidation; secondary prevention; suicide; therapy
Mesh:
Year: 2018 PMID: 29734740 PMCID: PMC5981960 DOI: 10.3390/ijerph15050921
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1This flowchart shows the flow of participants in the study.
Scores of SMFQ and WHO-5 before and after treatment in the MR-CBT-group and the TAU group (per protocol analysis). Mean (minimum-maximum).
| MR-CBT | TAU | ||||||
|---|---|---|---|---|---|---|---|
| Effect variable | Baseline | End of treatment | Baseline | End of treatment | |||
| SMFQ | 16.9 | 6.7 | <0.01 | 16.4 | 8.8 | <0.01 | 0.2 |
| WHO-5 | 28(4–68) | 63(24–92) | <0.01 | 32(4–60) | 69(48–76) | <0.05 | 0.6 |
* Difference in score baseline/endpoint Wilcoxon matched pairs test. # Difference in score between MR-CBT and TAU at endpoint Mann-Whitney U-test.